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ABBREVIATIONS 
CCHFV Crimean-Congo hemorrhagic fever virus 
CHIKV Chikungunya virus 
CHPV Chandipura virus 
CI Confidence interval 
CSF Cerebrospinal fluid 
CTFV Colorado tick fever virus 
CVV Cache Valley virus 
DENV Dengue virus 
EEEV Eastern equine encephalitis virus 
JEV Japanese encephalitis virus 
KFDV Kyasanur Forest disease virus 
LACV La Crosse virus 
LIV Looping ill virus 
MAYV Mayaro virus 
MTCT Mother to child transmission 
OR Odds ratio 
ONNV O’Nyong nyong virus 
OROV Oropouche virus 
RRV Ross River virus 
RT-PCR Reverse-transcriptase polymerase chain reaction 
RVFV Rift Valley fever virus 
SFTSV Severe fever and thrombocytopenia syndrome virus 
SINV Sindbis virus  
SLEV Saint Louis encephalitis virus 
TBEV Tick-borne encephalitis virus 
TOSV Toscana virus 
VEEV Venezuelan equine encephalitis virus 
WEEV Western equine encephalitis virus 
WG Weeks of gestation 
WNV West Nile virus  
YFV Yellow fever virus 
ZIKV Zika virus 
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ABSTRACT 
Arboviruses are an expanding public health threat, with pregnant women facing unique complications. Arbovirus 
infections can be more severe in pregnant women than in the general population, for e.g. dengue and Crimean-
Congo hemorrhagic fever. Vertical transmission is reported for many arboviruses and can severely affect 
pregnancy outcome. Indeed, arboviruses are associated with increased risks of fetal losses and prematurity, in 
particular Flaviviruses and Alphaviruses. Arboviruses can be teratogenic, as for Zika virus and Venezuelan 
equine encephalitis virus. Intrapartum transmission can finally result in severe neonatal infections, as for 
Chikungunya virus. Although the global burden of arboviruses is well recognized, little data focus specifically 
on mother-child health and arbovirus infection. Epidemiological and clinical studies are therefore needed to 
better assess the burden of arbovirus infections during pregnancy and improve their prevention and clinical 
management. Here we review available information and point out gaps of knowledge requiring further 
assessment. 
 
INTRODUCTION 
Arboviruses are viruses transmitted by arthropod vectors. More than 100 arbovirus species are pathogenic to 
humans. They belong to six main RNA virus families (Togaviridae, Flaviviridae, Bunyaviridae, as well as 
Reoviridae, Rhabdoviridae and Orthomyxoviridae), and therefore exhibit a high level of genetic variability. 
Arbovirus infections typically manifest as fever, possibly associated with cutaneous, joint, neurological and/or 
hemorrhagic symptoms and signs. 
The recent emergence of Zika virus and the identification of its teratogenicity illustrate the threat posed by 
arboviruses to pregnant women and their fetus, and many other arboviruses are associated with maternal-fetal 
pathologies.1  All inhabited continents face emerging, re-emerging or highly endemic arbovirus infections, as 
illustrated by the recent outbreaks of Zika virus, of Chikungunya virus which has spread from Africa to the 
Indian Ocean, Asia and the Americas, or of West Nile virus (which spread throughout North America over the 
last decade; by the increasing burden of Dengue virus (108 cases / year globally); and by the recent reemergence 
of Yellow fever virus infections (2 x 105 cases / year globally).2-4 Of the estimated 210,000,000 annual 
pregnancies worldwide, 90% occur in areas where arboviruses are endemic or epidemic, while the remaining 
10% pregnant women may be exposed sporadically, considering the increasing number of pregnant travelers.5,6 
As an illustration of arbovirus threat to pregnant women, it is estimated that around 10% of pregnant women 
were infected by Chikungunya virus during the 2005-2006 outbreak in La Réunion, and 2·8% of Brazilian 
pregnant women had serological evidence of recent Dengue virus infection in the 2008-2009 outbreak.7,8 As of 
April 2017, around 17,000 pregnant women have been infected by Zika virus in Brazil alone.9 Considering that 
arbovirus infections are under-diagnosed and underreported in endemic areas, the actual number of infected 
pregnant women is likely far larger. 
The threat of arbovirus infections during pregnancy may expose to three distinct risks: (i) more severe infection 
in pregnant women than in the general adult population, (ii) mother-to-child transmission (MTCT) before 
delivery (antepartum) with deleterious consequences on pregnancy and fetus, including teratogenic effects, and 
(iii) MTCT during delivery (intrapartum) resulting in severe neonatal infection. The severity of these potential 
complications contrasts with the current lack of available detailed clinical data, preventive and curative 
strategies.10,11 Here we review the available epidemiological, virological, clinical and therapeutic data on major 
arbovirus infections in pregnancy and identify gaps of knowledge that need to be addressed on this important 
biomedical topic. 
 
 
EPIDEMIOLOGY AND VECTORS 
The classification and epidemiological features of the main arboviruses responsible for human diseases are listed 
in table 1, 2 and 3.  
Human arboviruses transmission involves three factors: (i) a vertebrate reservoir, (ii) blood-sucking arthropods 
that act as biological vectors, and (iii) the human host that can be infected as spillover events and become 
secondary reservoir in urban settings, such as for Dengue virus, Chikungunya virus and Zika virus.3,4 The array 
of vectors involved is usually narrow for a given arbovirus species, but involves altogether a wide variety of 
species of mosquitoes, ticks, midges, and sandflies. 
Arboviruses are widely distributed (figure 1 A-C), reflecting multiple factors that include the type, competence 
and distribution of their respective vector(s); geographic and climate variables; presence of enzootic cycles 
acting as amplifying reservoirs.56 As a result, the geographic distribution of arbovirus species is uneven and 
constantly evolving. Some arboviruses are, at least so far, restricted to specific regions: Japanese encephalitis 
virus is present in Asia where Yellow fever virus is absent 57, Dengue virus circulates in all tropical/subtropical 
areas and Tick-borne encephalitis virus only in Central and Eastern Europe, and Asia.58,59 Other arbovirus 
species have (re)-emerged as local outbreaks, and then spread on a large scale, like West Nile virus which 
emerged on the East of the USA in 1999, and then spread to the West coast in the next 5 years; Chikungunya 
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virus which spread from East Africa to the Indian Ocean and Asia (2004-2007) and emerged in the Americas in 
2014; or Zika virus, originating from Africa, which emerged in the Pacific Islands in 2008 and reached South 
and Central Americas in 2015 from where it has since amplified massively.3,4 Imported travel-related cases have 
also resulted in clusters of autochthonous arbovirus transmission in temperate areas where their vector is 
implanted, like Chikungunya virus in Italy in 2007.60 Other arboviruses remain geographically very limited, like 
Kyasanur Forest disease virus in Karnataka state in India, Oropouche virus, Mayaro virus or Cache Valley virus 
in America, but these viruses might spread if conditions promoting transmission arise.61 For example, in Egypt, 
the Aswan dam construction was responsible for major vector amplification that led to  Rift Valley fever virus -
related abortion storms in cattle and subsequent spread of this epizootic to humans.62 Climate changes have also 
been proposed as a possible trigger of Bunyaviridae spreading around the Mediterranean basin, and in particular 
of Crimean-Congo hemorrhagic fever virus in Madrid, Spain in August 2016.63,64 These unanticipated cases 
illustrate the possibility of arbovirus emergence outside of the tropics if the right conditions are met. The factors 
responsible for the current global arbovirus outburst have been extensively studied.3 They combine 
anthropogenic factors (increased human transportation, deforestation, urbanization, rainwater storage, poor 
sanitation conditions), inefficient vector control/resistance to insecticides, and climate change including El Niño 
and global warming).56 These conditions favor contacts between permissive hosts and competent vectors and 
also facilitate vector amplification and extension beyond tropical latitudes. Selection of virus variants, through 
emergence of isolates with enhanced virulence and/or enhanced vector or vertebrate host fitness have also been 
proposed.3 
 
MATERNAL CLINICAL PRESENTATION 
As in the non-pregnant host, arbovirus infections typical clinical presentation in pregnant women varies 
according to the virus involved but they share common features. Incubation is short, typically less than a week 
after arthropod bite. Three main patterns are observed, which may overlap: 
- Fever and flu-like symptoms with or without rash (e.g.  Zika virus, Dengue virus, Chikungunya virus, 
Oropouche virus, and West Nile virus) 
- Encephalitis/meningoencephalitis (e.g. Japanese encephalitis virus, Tick-borne encephalitis virus, Saint 
Louis encephalitis virus, Venezuelan equine encephalitis virus, Western and Eastern equine 
encephalitis viruses, La Crosse virus, Ross River virus, West Nile virus, Toscana virus, Colorado tick 
fever virus and Chandipura virus, and less commonly Dengue virus, Chikungunya virus and Zika virus) 
- Hemorrhagic fever (e.g.  Yellow fever virus, Rift Valley fever virus, Crimean-Congo hemorrhagic fever 
virus and Dengue virus). 
Yet, in most cases and for most arboviruses, infection is asymptomatic, with the notable exceptions of 
Chikungunya virus 2 (symptomatic in above 85%), of Yellow fever virus 65 and Asian lineage of Zika virus 
(symptomatic in 50%). 66 Mortality varies according to the causative agent and clinical presentation. It is 
reported in up to 30% in hemorrhagic fever and/or shock syndrome complicating Crimean-Congo hemorrhagic 
fever virus, Japanese encephalitis virus, Yellow fever virus, Tick-borne encephalitis virus, and Dengue virus 
infections, but anecdotally reported in others. Most infections resolve without sequelae, except those caused by 
neurotropic viruses that can result in long-term neurological defects. For instance, Japanese encephalitis virus, 
which mostly affects children, is responsible for persisting neurological disabilities in more than 30% of 
surviving patients.59 Also, less severe complications such as long-lasting articular disease or persisting fatigue 
after viral clearance can be reported with arthrogenic alphaviruses (mainly Chikungunya virus, Mayaro virus, 
and Ross River virus) and Dengue virus, respectively. 
Until recently, pregnancy was not identified in epidemiological studies as a specific risk factor for severe 
arbovirus infection, in contrast to other infections like influenza, varicella, measles and malaria that are notably 
more severe during pregnancy. Hemorrhagic symptoms are a threat to pregnant women, and the two notable 
exceptions to this rule are Dengue virus and Crimean-Congo hemorrhagic fever virus, both arboviruses 
associated with hemorrhagic complications.67,68 Indeed, arbovirus hemorrhagic complications not only increase 
maternal mortality, but also expose infected mothers to higher rates of C-section and post-partum hemorrhages 
with additional life-threatening consequences.50,69 Indeed, a significant increase in severe dengue (dengue 
hemorrhagic fever and/or shock syndrome) has been reported in pregnant women in Brazil, especially during the 
second and third pregnancy trimesters, as compared to non-pregnant women of reproductive age (odds ratio 
[OR] 3·38; Confidence interval [CI] 2·10-5·42).11 The mortality rate reached 22% in pregnant Sudanese women 
diagnosed with dengue hemorrhagic fever and/or shock (mortality of non-pregnant women of reproductive age 
was not reported in this study).70 Maternal mortality rate reached 34% in pregnant women with Crimean-Congo 
hemorrhagic fever, which is likely higher than in the general population.48,49 
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FETAL AND NEONATAL CONSEQUENCES OF MATERNAL INFECTION 
When maternal arbovirus infection is reported, obstetrical follow-up should include evaluation of placental 
function, of fetal vitality and growth, with careful ultrasound detection and characterization of fetus 
developmental defects and of clinical and radiological neonatal abnormalities. Few arboviruses have been 
studied in detail with regard to their direct and indirect impact on the fetal-placental unit, and almost all available 
data are derived from the arboviruses of the Togaviridae and Flaviridae families. The spectrum of fetal and/or 
neonatal complications encompasses: 
- Fetal losses (miscarriages < 28 weeks of gestation (WG) and stillbirths thereafter)9 (mostly for Dengue 
virus, Japanese encephalitis virus, Zika virus, and Venezuelan equine encephalitis virus), premature 
delivery and low birthweight for gestational age (mostly Dengue virus) 
- Developmental defects/teratogenicity (Zika virus and Venezuelan equine encephalitis virus) 
- Perinatal infection (defined as neonatal infection occurring either upon intrapartum contamination, or 
after late antepartum contamination, within the last days of pregnancy) (Chikungunya virus, to a lower 
extent Dengue virus and as case reports Yellow fever virus, Zika virus, and Western equine encephalitis 
virus)12,21,22,27,29,30,38,42,47,69,71 
-  
Dengue virus: Dengue virus is associated with a significant risk of adverse fetal outcome. In a recent meta-
analysis, Paixao et al. evidenced that overt dengue is associated with an increased risk of miscarriage (OR 3·51, 
95% CI 1·15–10·77), of stillbirth (crude relative risk 6·7, 95% CI 2·1–21·3), preterm birth (OR 1·71, 95% CI 
1·06–2·76), and low birthweight for gestational age (OR 1·41, 95% CI 0·90–2·21).27,29 Fetal losses are reported 
until 25 WG.27 Fetal losses correlate with maternal symptoms’ severity, and fetal loss rates in mothers with 
asymptomatic infection does not differ from the pregnant uninfected population.29 Brazilian data suggest that 
maternal sickle cell disease, a genetic trait highly prevalent in Latin America and Africa, might increase dengue-
associated risk of fetal loss.72 Whether serotype has an impact on fetal loss remains unknown. Perinatal Dengue 
virus transmission is also reported in case of maternal symptoms occurring 10 days around delivery, yet its 
actual incidence is unknown.30,73 Of note, maternal Dengue virus-specific antibodies passively transmitted to the 
fetus confer protection for neonates towards dengue at first, but also increases the risk of severe infection in 
dengue involving another Dengue virus serotype. This phenomenon, referred to as antibody-dependent 
enhancement, results from antibody-mediated facilitation of virus infection of FCR-bearing cells.74,75 
Japanese encephalitis virus: Japanese encephalitis virus is responsible for miscarriages that are only reported 
when maternal infection occurs until 22 WG (4/4 aborted fetuses with evidence of Japanese encephalitis virus 
infection until 22 WG versus 0/4 cases after 22 WG in the only available case series).32,76  
 West Nile virus: A single observation reported a congenitally acquired West Nile virus-associated encephalitis 
and chorioretinitis after maternal infection at 27 WG, but subsequent large epidemiological studies showed no 
increased risk for fetal infection or demise, nor any long-term neurological impairment in children borne from 
mothers infected during their pregnancy.35,77,78 
Venezuelan equine encephalitis virus: Venezuelan equine encephalitis virus is associated with frequent 
miscarriages, stillbirths and premature deliveries, as observed during the large 1962 and 1995 Venezuelan 
outbreaks. Autopsies could be performed in 10 cases and Venezuelan equine encephalitis virus was evidenced in 
the brain of aborted fetuses.2,20 Single observations of infants born to mothers who experienced Venezuelan 
equine encephalitis between 13 to 36 WG also evidenced neurological disorders that led to classify Venezuelan 
equine encephalitis virus as the first teratogenic arbovirus.79 These infants presented with fatal cerebral lesions 
ranging from extensive necrosis to hydranencephaly, with neuronal and astrocytes abnormalities.79 Of note, 
Venezuelan equine encephalitis virus is an alphavirus, which belong to Togaviridae family that also includes 
Rubella virus, a notorious teratogenic virus associated with a severe congenital syndrome. 
Zika virus: Asian lineage Zika virus has recently emerged, and medical observations as well as experimental 
investigations have led to the conclusion that Zika virus is a major teratogenic arbovirus, and the only one so far 
of the Flaviviridae family in human. Zika virus was until 2015 considered as causing only a benign illness in 
rural areas of Africa, where it is endemic, before it emerged in Micronesia (5,000 people affected), French 
Polynesia (100,000) and massively spread to Latin America, where Zika virus high incidence in a non-immune 
population living in a highly-medicalized area led to the identification of its association with fetal 
complications.39,80 Data collected in Brazil, and retrospective analysis of data from French Polynesia 
demonstrated the temporal and geographical association between Zika virus infection in pregnant women and 
fetal losses, growth restriction or fetal and neonatal developmental defects, initially identified as 
“microcephaly”.39,81 Altogether, the “congenital Zika syndrome” now includes microcephaly, which can be 
associated to other brain abnormalities that include eye lesions (including malformations, optic neuritis, 
chorioretinal scarring and atrophy), hearing loss, cranio-facial and musculoskeletal lesions likely resulting from 
fetal akinesia deformation sequence (arthrogryposis, lung hypoplasia, flat midface, scoliosis, and limb 
deformations).82,83 Autopsy data have evidenced cerebral ventriculomegaly, lyssencephaly, cerebellar hypoplasia 
and agyria.84-87 Microscopic brain lesions include micro-calcifications, gliosis, neuronal and glial cells 
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degeneration and necrosis located at the subcortical-cortical transition, and also perivascular infiltrate of T and B 
cells in the subcortical white matter and Wallerian degeneration of the long descending tracts.87 Reduced 
placental function with fetal growth restriction and fetal loss is also reported when maternal infection occurs up 
to 32WG.42 The rate of brain abnormalities at birth in infants born from  Zika virus -infected mothers is 
estimated from 1% to 13%39,40, with a recent 5.9% estimation in an cohort from the USA.43 The peak of fetal 
susceptibility to Zika virus congenital syndrome appears to be the first trimester of pregnancy, although 14% of 
infants with Zika virus -associated microcephaly in the Brazilian cohort had maternal infection in the second 
trimester; brain calcification and hemorrhages have also been evidenced in 2 fetuses infected at 34 and 39WG, 
respectively.42 Long-term postnatal neurological consequences of Zika virus fetal infection remain to be fully 
determined. A preliminary study on 48 Brazilian infants report poor cranial growth, irritability, 
pyramidal/extrapyramidal symptoms, and epilepsy at up to 8 months of age, including in children without 
microcephaly at birth.	46 
Chikungunya virus: Chikungunya virus is responsible for neonatal infection that occurs as a consequence of 
intrapartum contamination and is now recognized from large epidemiological studies as a major complication of 
maternal chikungunya.8 Vertical transmission occurs in up to half of mothers who are viremic during labor.12 
Neonatal symptoms develop between 3-7 days of life, and range from mild presentation (43%) to severe 
infection with encephalitis (53%) requiring transfer in intensive care unit.8 Fever and acute respiratory distress 
are also reported.12 This presentation is hardly distinguishable from bacterial sepsis, and diagnosis is challenging 
when maternal infection has not been diagnosed. Neonatal Chikungunya neurological disease can have a 
dramatic impact on postnatal neurological development: recent data evidence a significantly lower median 
Development Quotient (86 versus 100, p<0.001) at the age of 2 years and a significant proportion of moderate to 
severe global neurodevelopmental delays (51% versus 15%, p<0.001) in infants with perinatal infection when 
compared to uninfected matched controls.88  
Ross river virus: In contrast to  Chikungunya virus -associated severe fetal outcomes, Ross river virus MTCT has 
been reported as asymptomatic, and associated with no neonatal pathology.17  
 
PATHOPHYSIOLOGY 
Mechanisms associated with increased maternal severity in dengue and Crimean-Congo hemorrhagic fever are 
unknown, although the impact of utero-placental hemorrhages might be involved, especially in low-resources 
countries where access to transfusion and surgery is limited. Fetal and neonatal complications may result from 
four complementary processes: (i) acute fetal distress in the context of a severe maternal infection impairing 
maternal hemodynamics, and therefore placental/fetal oxygenation, (ii) placental arbovirus infection with 
subsequent reduction of the blood flow to the fetus without fetal infection, (iii) fetal and neonatal infection in the 
context of virus crossing of the placental barrier, and (iv) neonatal infection in the context of labor-associated 
placental breaches (figure 2).89 
Maternal hemodynamic changes might have an impact on placental perfusion and thereby on the developing 
fetus. This has been recently suggested for dengue. Indeed, histopathological analyses of placenta collected at 
delivery from  Dengue virus -infected mothers have evidenced hypoxic lesions with villous stroma edema, 
infarcted and pre-infarcted areas in 19/24 cases, including 8 from mothers who did not report overt shock 
syndrome.72 This is also the most likely scenario accounting for fetal losses in severe Crimean-Congo 
hemorrhagic fever, although not proven. 
Placental arbovirus infection can induce placental dysfunction, with subsequent adverse fetal outcome. It is one 
of the most likely causes of the fetal losses, premature deliveries and low birthweights reported in dengue. 
Indeed, the same histopathological studies also evidenced chorio-deciduitis and villitis; immunostaining 
evidenced viral antigens in the decidual cells trophoblasts and villous stroma cells in 22/24 cases that overlapped 
with histological lesions in 10.72 
Placental arbovirus infection can also lead to antepartum MTCT, which can either be asymptomatic, lead to fetal 
death, and/or to developmental defects (teratogenicity). MTCT associated with fetal death has been poorly 
studied in human, and is only documented for Zika virus and Japanese encephalitis virus, but largely reported in 
other mammals for many arboviruses, like Venezuelan equine encephalitis virus in mice and mares, Western 
equine encephalitis virus in rhesus macaques, Ross river virus in mice, Japanese encephalitis virus in swine and 
West Nile virus in mice or Rift valley fever virus in ruminants.8,90-93 The events and timing associated with 
fetal/litter losses are far from being fully elucidated. It is assumed that the sooner the maternal infection occurs, 
the most severe the fetal consequences are, as evidenced in mice for West Nile virus and Japanese encephalitis 
virus, and in Japanese encephalitis virus in humans as reported above.93,94 
Veterinary medicine observations of developmental defects in the offspring after epizootic events has provided 
the first basis incriminating arboviruses as teratogenic, long before the ongoing Zika virus outbreak. 
Developmental defects include brain lesions, whatever the arbovirus family involved, in line with the 
observation that most other vertically transmitted-pathogens are also neurotropic, like Rubella virus, bacteria 
such as Listeria monocytogenes, Treponema pallidum, and protozoans such as Toxoplasma gondii. A teratogenic 
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effect has been reported for Rift valley fever virus and Cache valley virus in calves, Saint Louis encephalitis 
virus in mice and with other animal arboviruses that have never been described in humans so far, like 
Wesselsbron virus (calves), Bovine viral diarrhea virus (calves) or Banzi virus (sheeps) (all Flaviviridae), 
Schmallenberg virus (calves) or Akabane virus (goats and calves) (both Bunyaviridae) or Blue tongue virus 
(calves) (Reoviridae).95-98 In humans, only Venezuelan equine encephalitis virus and Zika virus have been 
proven teratogenic. Venezuelan equine encephalitis virus was first incriminated in 1977, but detailed 
pathophysiological data are not available. Experiments performed in rats evidenced the presence of viral 
antigens on the cyto- and syncytiotrophoblasts.99 Venezuelan equine encephalitis virus was confirmed 
teratogenic in a Rhesus monkey model of infection (microcephaly, hydrocephaly), however the mechanisms of 
viral crossing of the placental barrier and teratogenicity have not been elucidated.100 In contrast, Zika virus 
pathogenicity has been extensively studied since 2015, in context of its massive dissemination in Latin America. 
Clinical, experimental and epidemiological studies have demonstrated the teratogenicity of Zika virus, based on 
temporality, biological plausibility, strength of association, exclusion of alternative explanations, cessation, 
animal experiments, consistency and analogy with other teratogenic pathogens (reviewed in 80). Zika virus 
exhibits unique properties responsible for the Zika virus congenital syndrome: it is able to cross the placental 
barrier, multiply in the placenta and disseminate to the fetus, targeting the cortical progenitors of the brain, 
thereby inducing microcephaly. Data from in vitro cultured cells and placenta explants show that Zika virus is 
able to infect the extra villous cytotrophoblast but not the mature syncytiotrophoblast.101,102 How Zika virus  
reaches these extra villous cytotrophoblastic cells that are not directly accessible from the maternal bloodremains 
to be elucidated. In the placenta, Zika virus can multiply in resident macrophages, called Hofbauer cells, as 
evidenced from histological data, explant and cultured cells experiments.101,103 They might amplify Zika virus 
infection, along with infected placental endothelial cells, and favor its release in the fetal circulation.82 In the 
fetus, Zika virus is neurotropic, with high viral RNA titers found in the brain, as compared to the lungs, spleen 
and liver.87,104,105 The mechanisms associated with Zika virus  access to the fetal brain remain to be uncovered. In 
the fetal brain parenchyma Zika virus seems to be the unique flavivirus able to infect cortical progenitors. It has 
also been recently evidenced in vitro that DENV-antibodies cross-react with Zika virus and thereby enhance 
Zika infection; this could have important clinical consequences as both viruses are highly prevalent in Latin 
America, and also for the development of vaccines against both viruses.106 
Intrapartum contamination without actual placental infection is a direct consequence of maternal viremia and 
fetal/neonatal susceptibility to a given arbovirus species. It has been well documented for Chikungunya virus, 
which, in contrast to Zika virus, is not able to infect the placenta.8,10 It is therefore not transmitted to the fetus in 
the absence of placental breaches, that allow a transfer of maternal blood to the fetal/neonatal circulation. 
Indeed, Chikungunya virus cannot be detected as replicating in the placenta from viremic mothers, and human 
syncytiototrophoblastic cell lines are refractory to infection in vitro.10 This was confirmed by experimental 
infections performed in a model of gestant IFN-α/βR-/- mice, where placentas constitute an absolute barrier to 
Chikungunya virus that protect highly susceptible fetuses from CHIKV infection despite high maternal 
viremia.10 
 
DIAGNOSIS OF ARBOVIRUS INFECTIONS 
Diagnostic procedures in pregnant women do not differ from those used in the general population. Biological 
abnormalities, that include lymphopenia, thrombocytopenia and increased serum transaminase levels, can mimic 
a pregnancy-associated complication called HELLP syndrome (that can precede eclampsia and is characterized 
by Hemolysis, Elevated liver enzymes, Low Platelet count), and therefore delay diagnosis. Virological diagnosis 
relies on arbovirus-specific reverse-transcriptase polymerase chain reaction (RT-PCR) assays in blood or 
cerebrospinal fluid (CSF), and on serological assays (IgM detection, IgG seroconversion and/or 4-fold increase 
in IgG titers on sera collected at 10-14 days’ interval). RT-PCR in the blood is limited to the diagnosis of the 
arboviruses responsible for high viremia during the first days of symptoms, like West Nile virus, Dengue virus, 
Chikungunya virus and Zika virus.65 Detection of virus-specific IgM in the CSF can also be performed.107 Zika 
virus RNA is also detectable in the urine for 14 to 21 days.108  
The diagnosis of fetal infection would be based on RT-PCR on amniotic fluid or fetal blood to prove MTCT. 
The added value of antenatal screening for arboviruses has not been precisely evaluated (and the procedure may 
actually favor MTCT), apart from Zika virus given its notable teratogenic effect, for which amniocentesis is 
considered on an individual basis, when pregnancy termination would be medically considered, and ethically and 
legally authorized.109 Clinicians should be aware that biological samples with suspected or demonstrated level-3 
(most arboviruses in non-endemic areas) and level-4 pathogens (like Crimean Congo hemorrhagic fever virus) 
require adequate management in authorized facilities. 
 
PREVENTION OF MATERNAL INFECTION 
Vector control and limitation of contact with arthropods is key for arbovirus infection prevention. General 
protective measures for pregnant women are similar to those for the general population, such as covering the 
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exposed skin, checking for tick-bites (for Crimean Congo hemorrhagic fever virus), using window and door 
screens, bed nets, and if possible air-conditioning. The use of insects repellent at recommended dosage is 
considered safe for pregnant women.110,111 
Commercial vaccines are available against Japanese encephalitis virus, Tick-borne encephalitis virus, and 
Yellow fever virus. There is no available data regarding the use of inactivated Japanese encephalitis virus and 
Tick-borne encephalitis virus vaccines during pregnancy. They do not expose the fetus to infectious risk, but 
given the lack of large cohort studies, they should only be administered after careful individual risk-benefit 
assessment.112 Most experts would recommend their use in pregnant women in case of high exposure to 
mosquito bite in areas of autochthonous arbovirus transmission. Live-attenuated Japanese encephalitis virus 
vaccines are not recommended during pregnancy. Even though the live-attenuated Yellow fever virus vaccine is 
classically contraindicated during pregnancy, the World Health Organization recommends its administration in 
pregnancy if travel to endemic area is unavoidable.113 This recommendation results from the apparent safety of 
yellow fever vaccine in pregnant women in large scale vaccination campaigns in Africa and Brazil, and from the 
severity of the disease and persisting burden in unvaccinated population.114,115 The first life-attenuated dengue 
vaccine was recently registered.116 The lack of data in pregnant women and usual restrictions about live vaccines 
in pregnancy precludes for now its use in this setting. A formalin-inactivated vaccine for Rift valley fever virus 
and an inactivated vaccine against Kyasanur Forest disease virus are also developed but not widely available; 
and there is no data on their use during pregnancy.117 To date, there is still no commercially-available vaccine 
against Chikungunya virus. Passive immunization with polyclonal immunoglobulins is effective in preventing 
Crimean Congo hemorrhagic fever virus, Rift valley fever virus and West Nile virus infections, but has not been 
studied in pregnancy.118-120 Regarding Zika virus, although there is a consensus that a vaccine able to prevent  
Zika virus -associated fetopathy is critically warranted, testing the efficacy and safety of such a vaccine in 
pregnant women is poised to be challenging, as risks associated with Zika virus to be prevented by vaccination 
should outweigh risks associated with the prescription of a new biological preparation in the pregnant host. 
 
MATERNAL ANTIVIRAL TREATMENT 
No specific anti-arbovirus drug is commercially available. Ribavirin has been considered useful in some 
extremely severe arbovirus diseases like Crimean Congo hemorrhagic fever virus and Rift valley fever virus, but 
its demonstrated teratogenic effect precludes its use during pregnancy, except in life-threatening maternal 
infections.121 BCX4430, an adenosine nucleoside analog with broad-spectrum antiviral properties against RNA 
viruses, is currently investigated. It has demonstrated in vitro activity towards Filoviridae, Bunyaviridae, and 
Flaviviridae, including mosquito-borne species (Yellow fever virus, Japanese encephalitis virus, Dengue virus 2, 
West Nile virus, African and Asian lineages of Zika virus) and tick-borne species (Tick-borne encephalitis virus, 
Kyasanur Forest disease virus, Looping ill virus).122 It has been reported as active in vitro and in vivo in a mouse 
model of Zika, and recently entered phase I human clinical studies in healthy volunteers with promising 
pharmacokinetics and tolerance.123,124 
Drug repurposing also suggest a potential antiviral effect for ivermectin and azithromycin. Ivermectin is an anti-
helminthic drug with antiviral properties that inhibits flaviviruses’ replication by targeting the NS3 helicase 
activity.125 A clinical trial is currently evaluating its efficacy in Thailand (NCT02045069). If proven beneficial, 
this would open new interesting opportunities for the treatment of maternal dengue, considering the safety of 
ivermectin during pregnancy.126 Azithromycin is a macrolide that is considered safe in pregnancy. It has recently 
been shown to exhibit an antiviral effect on  Zika virus.127 
Whole genome RNAi and CRISPR/Cas9 screens have helped identify multiple druggable host pathways for 
which antiviral development is currently under way.128,129 
  
NEONATAL THERAPEUTIC STRATEGIES 
Passive immunotherapy by infusion of immunoglobulins can prevent MTCT, as reported for Hepatitis B.	They 
can reduce viral load and therefore the burden of neonatal infection.130 Such strategies could be extremely 
promising in the field of arbovirus infections. 
Polyvalent immunoglobulins purified from plasma obtained from chikungunya-convalescent human donors have 
been shown protective and curative in a mouse model of chikungunya.131 Anti-chikungunya virus hyper-immune 
immunoglobulins are under evaluation to assess their safety and efficacy in the prevention of chikungunya virus 
MTCT in neonates born to viremic mothers (CHIKIVIG-01, clinical trials NCT02230163). Similar approaches 
have been reported against West Nile virus but not evaluated in pregnancy.132 
 
GAPS IN KNOWLEDGE 
Key messages from this review are (i) the severity of maternal Dengue and Crimean-Congo hemorrhagic fever, 
(ii) the risk of fetal losses associated with flaviviruses (Dengue virus and Japanese encephalitis virus), (iii) the 
teratogenicity of Zika virus and Venezuelan equine encephalitis virus, and (iv) the severity of intrapartum 
arbovirus MTCT, in particular for Chikungunya virus. However, there remain many unknowns regarding the 
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actual burden of arbovirus infections during pregnancy. 
The true incidence of arbovirus infections in pregnancy has not been precisely assessed, nor the true incidence of 
adverse fetal outcome.133 This lack of knowledge results from a combination of parameters: (i) epidemiological 
factors (co-existence of different arboviruses in the same geographic areas, current rarity of some arbovirus 
infections) (ii) medical factors, as most arbovirus infections can be asymptomatic; (iii) socio-economic factors, 
considering the worldwide heterogeneity of health care access for pregnant women and neonates, of diagnostic 
procedures availability, of care seeking behavior for self-limited infections or fetal loss, and finally (iv) 
methodological factors, as many studies lack the statistical power to detect obstetrical consequences in contexts 
of low/unknown arbovirus incidence.19,134,135 Dedicated prospective studies, based on large population data are 
urgently needed, along with the systematic report of sporadic cases, including imported cases in high-resource 
countries. Sustainable and interconnected surveillance systems are mandatory to better assess epidemiological 
signals. Current evidence argues for a more systematic and exhaustive laboratory work-up in cases of fetal loss 
or fever with compatible syndromes in pregnant women, and for a systematic assessment of long-term 
developmental consequences in congenital arbovirus infections. 
Pathophysiological mechanisms responsible for arbovirus-associated increased maternal severity, fetal losses, 
developmental defects and neonatal pathology remain understudied. Zika virus is a remarkable illustration of 
how the detailed study of a virus and the pathologies it induces can progress dramatically within a 1-year 
window. Similar studies are now critically needed for other highly prevalent arboviruses which are here to stay, 
and for which a precise characterization of their impact on pregnancy is lacking. 
Finally, therapeutic trials dedicated to mother and child issues are also urgently needed: infectious diseases 
remain the first cause of maternal death worldwide.136 Improving our understanding of arbovirus infections in 
pregnancy and their medical management might turn out to help reach two of the eight millennium 
developmental goals set by the United Nations and the Bill and Melinda Gates Foundation: improve maternal 
health and reduce child mortality.137 
SEARCH STRATEGY AND SELECTION CRITERIA 
We searched in PubMed, Embase, Web of science (Thomson Reuters) and Cochrane Central databases for all 
reports published up to March 31, 2017 using the terms “arbovirus”, “pregnancy”, “newborn”, “fetal” and 
“placenta”. A second search was performed replacing the generic term “arbovirus” with the name of each 
individual known arbovirus, such as “Chikungunya”, Venezuelan equine” Japanese encephalitis”, Dengue” and 
so on. The complete list of terms and search strategy are available in supplementary material. Language 
restrictions were: English, French, Spanish and German. 
KEY MESSAGES 
• Dengue and Crimean-Congo hemorrhagic fever infections are more severe in pregnancy
• Flaviviruses and especially Dengue virus and Japanese encephalitis virus are associated with increased
risk of fetal losses
• Zika virus and Venezuelan equine encephalitis virus are teratogenic
• Intrapartum arbovirus Mother-to-child transmission may cause severe neonatal disease, in particular for
Chikungunya virus
• The actual burden of arbovirus infections during pregnancy remain uncovered.
Legends 
Figure 1. World distribution of major arbovirus infections. 
Figure 2. Patterns of pathophysiological events associated with adverse fetal/ neonatal outcome. 
Table 1. Classification, epidemiological features, maternal risk and consequences of mother to child 
transmission of major Togaviridae in humans. 
WG: Weeks of gestation 
USA: United States  
Miscarriages refer to fetal losses < 28 WG 
Stillbirths refer to fetal losses ³ 28 WG 
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Table 2. Classification, epidemiological features, maternal risk and consequences of mother to child 
transmission of major Flaviviridae in humans. 
WG: Weeks of gestation 
USA: United States  
Miscarriages refer to fetal losses < 28 WG 
Stillbirths refer to fetal losses ³ 28 WG 
Table 3. Classification, epidemiological features, maternal risk and consequences of mother to child 
transmission of major Bunyaviridae, Reoviridae and Rhabdoviridae in humans 
WG: Weeks of gestation 
USA: United States  
Miscarriages refer to fetal losses < 28 WG 
Stillbirths refer to fetal losses ³ 28 WG 
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Table 1. 
Family / virus Area Main vectors Maternal risk Antenatal consequences of mother to child transmission 
Perinatal consequences  
of mother to child transmission 
Barmah forest 
disease virus 
(BFDV) 
Australia Mosquito 
(Culex sp.) 
No data No data No data 
Chikungunya 
virus  
(CHIKV) 
America 
(tropical areas) 
Africa 
Asia 
Australia 
Indian Ocean 
Mosquito 
(Aedes sp.)  
No increased risk of severe 
maternal infection 
Transmission documented  
Low incidence 
- Miscarriages documented in 2% in one study (3/678) (No 
increase of stillbirths, prematurity or malformation 8) 
Documented  
Incidence: transmission rate of 28-49% with severe 
neonatal infection in 53% of newborn 
(encephalopathy) in one study 8,12 
- Severe neonatal infection with encephalopathy in 4 
studies 8,13-15
Eastern equine 
encephalitis 
virus (EEEV) 
America  
(North, Central and South) 
Mosquito 
(Culiseta sp.) 
No data No data No data 
Mayaro virus 
(MAYV) 
South America Mosquito 
(Aedes sp.) 
No data No data No data 
O’Nyong-nyong 
virus  
(ONNV) 
Central Africa Mosquito (Anopheles sp.) No data Transmission uncertain 
- 2 miscarriages reported, but link to infection unknown 
(fetuses untested) 16 
No data 
Ross river virus 
(RRV) 
Australia 
Pacific area 
Mosquito  
(Aedes sp. and Culex sp.) 
No data Transmission documented  
- 3% asymptomatic transmission in one single series 17 
No data 
Sindbis virus  
(SINV) 
Africa 
Asia 
Australia 
Europe (Fennoscandia) 
Mosquito  
(Aedes sp., Culex sp., and 
Culiseta sp.) 
No data Transmission uncertain 
- 2 stillbirths reported, including one following overt maternal 
infection at 32 WG (fetuses untested) 18 
No data 
Venezuelan 
equine 
encephalitis 
virus 
(VEEV) 
America  
(Central and South) 
Mosquito 
(Culex sp.) 
No data Transmission documented  
Incidence unknown  
(data from 2 small case-series) 
- VEEV documented in the brain of 10 aborted fetuses 19 
- Developmental brain lesions in infants born from mothers 
infected 13-36 WG 20 
No data 
Western equine 
encephalitis 
virus (WEEV) 
America  
(North, Central and South) 
Mosquito  
(Aedes sp. and Culex sp.) 
 No data No data Documented 
Incidence unknown 
- 3 cases with severe encephalitis, including one fatal 
21,22
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Table  2. 
Family / virus Area Main vectors Maternal risk Antenatal consequences of mother to child transmission 
Perinatal consequences  
of mother to child transmission 
Dengue virus 
(DENV) 
Worldwide (Tropical areas)  Mosquito 
(Aedes sp.) 
Documented risk of severe 
infection: hemorrhagic and/or 
shock syndrome  
Odds ratio 3·38 from a recent 
meta-analysis 11, 23-26 
Transmission documented 
- Increased rate of fetal losses in the first half of pregnancy 
(data from multiple cohorts, confirmed in a meta-analysis) 27-29 
Documented  
Incidence unknown 
- Severe neonatal infection with sepsis-like symptoms 
and acute respiratory distress reported as case-reports 
30, 31
Japanese 
encephalitis 
virus (JEV) 
Asia 
Australia 
Mosquito 
(Culex sp.) 
No data Transmission documented and severe  
Incidence unknown 
- Fetal losses documented only in maternal infections occurring 
< 22 WG (1 Indian series of 8 cases) 32 
No data 
Kyasanur forest 
disease / 
Alkhurma virus 
(KFDV) 
Asia (Middle East, India 
South-East and Western Asia) 
Tick 
 (Haemophysalis sp.) 
No data No data No data 
Murray Valley 
encephalitis 
virus (MVEV) 
Australia  
Papua New Guinea 
Mosquito 
 (Culex sp.) 
No data No data No data 
Powassan virus North America Tick 
(Ixodes sp.)  
No data No data No data 
Saint Louis 
encephalitis 
virus (SLEV) 
America (North and Central) Mosquito 
(Culex sp.) 
No data No data No data 
Tick-borne 
encephalitis 
virus (TBEV) 
Northern Europe and North 
Asia (in a belt extending from 
eastern Europe to Japan) 
Tick 
(Ixodes sp.) 
No data No data No data 
West Nile virus 
(WNV) 
(also known as 
Kunjin virus in 
Oceania) 
Worldwide  
Most prevalent in America 
and Africa 
Low prevalence in Europe  
Mosquito 
(Culex sp.) 
No data Transmission documented  
 Exceptional 
- One case of congenital chorioretinitis and encephalitis after 
maternal infection at 27 WG 33 
- No significant increase in fetal losses/adverse long term 
neurological outcome in US cohort studies 34-36 
Uncertain 
- 2 cases with encephalitis developing 6-10 days after 
birth (maternal symptoms 21-6 days before delivery, 
no documentation of viral infection at birth) 35  
- 1 case with transient rash at birth and positive IgM 1 
month later (maternal symptoms at birth) 35 
Yellow fever 
virus (YFV) 
Sub-Saharan Africa 
South America 
Mosquito (Aedes sp. or 
Haemagogus sp.) 
No data Transmission documented  
Exceptional 
- 2 cases of fatal maternal infection at 4 and 5 months of 
pregnancy with lesions compatible with YFV in the fetuses 37 
Documented 
Probably exceptional  
- One single fatal report (maternal symptoms onset 3 
days before delivery) 38 
Zika virus 
(ZIKV) 
South Pacific area 
Latin America Caribbean 
USA (Florida & Puerto Rico) 
Mosquito 
(Aedes sp.) 
Transmission documented  
Incidence : 1-13% brain abnormalities at birth39, 40 
-Demonstrated teratogenic according to multiple case-reports 
and case series 41 
- Severe microcephaly and other brain lesions 39 , 42, 43 
- Retinal lesions	44 
- Prematurity or fetal losses 45 
- Organogenesis and weight usually preserved 45 
- Impaired postnatal neurological development with poor 
cranial growth, irritability, pyramidal/extrapyramidal 
symptoms, and epilepsy.46 
Documented 
Probably exceptional  
- 2 French Polynesian case reports of possible perinatal 
transmission (one asymptomatic, one with mild rash)47 
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Table 3. 
Family / virus Area Main vectors Maternal risk Antenatal consequences of mother to child transmission 
Perinatal consequences  
of mother to child transmission 
Crimean-Congo hemorrhagic 
fever virus (CCHFV) 
Europe (South-East and Eastern)  
Africa 
Middle East Asian countries 
south of the 50th parallel  
Midge  
(Culicoides sp.) 
Tick  
(> 30 species involved) 
Documented increased risk of 
severe infection:  
Increased mortality rate 
(34% in a recent review of 42 
available case reports and short 
case series) 48 
Transmission documented 
Incidence unknown 
- 4 miscarriages at 4-19 WG (fetuses untested) (reviewed in 48) 
- Stillbirths with maternal death (data from two case series) 48, 49 
Documented 
Incidence unknown  
- One case with documented fatal neonatal infection 	50 
La Crosse virus (LACV) North America (Mid-western and 
eastern) 
Mosquito  
(Aedes sp.)  
No data Transmission documented  
Incidence unknown 
- One asymptomatic mother-to child transmission documented 
serologically in cord serum, after a maternal infection at 21 WG 51 
No data 
Oropouche virus (OROV) America (Central and South)  Midge  
(Culicoides sp.) 
No data No data No data 
Rift Valley fever virus 
(RVFV) 
Africa 
Middle East 
Asia 
Mosquito (Aedes sp., Culex 
sp. and Anopheles sp.) 
No data Transmission documented 
-Increased risk of miscarriages in a recent cross-sectional study 
comparing miscarriages in pregnant patients with documented 
RVFV (15/28, 54%) versus 12/103 (12%) in pregnant women with 
documented CHIKV infection 52 
Documented 
Incidence unknown  
- 2 symptomatic cases. Infants borne from mothers 
symptomatic 4-6 days before delivery. Symptoms were 
present at birth or 4 days after delivery (one with rash 
and organomegaly, and one with disseminated fatal 
infection). 53, 54
Severe fever with 
thrombocytopenia syndrome 
virus (SFTSV) 
Asia  
(Eastern China 
Japan and Corea) 
Not completely elucidated 
Evidenced in Ticks 
Haemaphisalis sp.) 
No data No data No data 
Tahyna virus (TAHV) Europe  
Africa 
Asia 
Mosquito  
(Culex sp.) 
No data No data No data 
Toscana virus (TOSCV) Europe Sand-fly (Phlebotomus sp.) No data No data No data 
Colorado tick fever virus 
(CTFV)  
North America Tick  
(Dermacentor sp.)  
No data Transmission uncertain  
- 2 miscarriages after maternal infections (fetuses not tested)55 
Uncertain 
One possible case (fever and leucopenia in a neonate 
delivered 6 days after maternal infection onset) 55 
Chandipura virus (CHPV) Asia  Sand-fly (Sergentomyia sp.) No data No data No data 
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